National rollout provides enhanced
accessibility to Niagen IV, a significant advancement in NAD+ IV
therapy
ChromaDex Corp. (NASDAQ:CDXC), the global authority on
nicotinamide adenine dinucleotide (NAD+) research with a focus on
healthy aging, today announced the nationwide rollout of its
pharmaceutical-grade nicotinamide riboside chloride (NRC) products,
Niagen® IV, now accessible at over 200 Restore Hyper Wellness
locations across the United States. This represents a major
milestone, making Niagen IV—a significant advancement in
intravenous NAD+ therapy—more widely accessible to wellness
enthusiasts looking to enhance cellular health and extend their
healthspan.
Available in oral and IV forms, ChromaDex’s clinically proven
patented ingredient, Niagen, is the most efficient, high-quality
NAD+ precursor available. NAD+ is a coenzyme that powers cells and
supports metabolic processes throughout the body, yet it declines
with age and due to everyday stressors like sun exposure, high-fat
diets, overtraining, and sedentary lifestyles—a decline linked to
both age-related and other health conditions.
The IV formulations support the rapid and efficient delivery of
Niagen. Outperforming NAD+ IV in the pilot clinical study, Niagen
IV offered superior tolerability, a 75% shorter infusion time, and
resulted in a statistically significant 20% increase in whole blood
NAD+ levels three hours post-infusion, as measured by NAD+ dried
blood spot tests (MedRxiv).
“Niagen IV is a superior solution to traditional NAD+ IV,” said
Rob Fried, CEO of ChromaDex. “We are pleased that reliably science
based Restore Hyper Wellness recognizes these advantages and is
offering Niagen IV nationwide.”
Restore Hyper Wellness, known for its innovative approach to
proactive health and wellness, provides access to advanced
modalities, with safety and efficacy as core principles. Restore’s
extensive network of clinics offers clients a holistic experience
designed to address their wellness goals and optimize physical
health.
“We’ve seen firsthand how Niagen IV elevates the wellness
experience for our clients, delivering enhanced cellular support
compared to NAD+ IV,” said Dr. Rachele Pojednic, Director of
Scientific Research & Education at Restore Hyper Wellness.
“Pharmaceutical-grade Niagen provides a cutting-edge option that
reflects our commitment to impactful, science-driven care.”
U.S. FDA-registered 503B outsourcing facility, Wells Pharma of
Houston, compounds and distributes pharmaceutical-grade Niagen for
clinics, which is available as Niagen IV exclusively for clinics,
such as Restore Hyper Wellness, with medical clearance.
To learn more about Niagen IV at Restore Hyper Wellness, visit
www.restore.com. Consumers can visit www.niagenplus.com to sign up
for product news and updates on future clinic availability and use
the store locator to find a clinic offering Niagen IV near you.
Forward-Looking Statements:
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities and Exchange Act of 1934, as
amended, including statements related to future increased
availability of pharmaceutical grade Niagen, and future performance
of pharmaceutical grade Niagen. Statements that are not a
description of historical facts constitute forward-looking
statements and may often, but not always, be identified by the use
of such words as "expects," "anticipates," "intends," "estimates,"
"plans," "potential," "possible," "probable," "believes," "seeks,"
"may," "will," "should," "could" or the negative of such terms or
other similar expressions. Risks that contribute to the uncertain
nature of these forward-looking statements include the impact of
the COVID-19 pandemic on our business and the global economy; our
history of operating losses and need to obtain additional
financing; the growth and profitability of our product sales; our
ability to maintain sales, marketing and distribution capabilities;
changing consumer perceptions of our products; our reliance on a
single or limited number of third-party suppliers; and the risks
and uncertainties associated with our business and financial
condition. More detailed information about ChromaDex and the risk
factors that may affect the realization of forward-looking
statements is set forth in ChromaDex's Annual Report on Form 10-K
for the fiscal year ended December 31, 2023, ChromaDex's Quarterly
Reports on Form 10-Q and other filings submitted by ChromaDex to
the SEC, copies of which may be obtained from the SEC's website at
www.sec.gov. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof, and actual results may differ materially from those
suggested by these forward-looking statements. All forward-looking
statements are qualified in their entirety by this cautionary
statement and ChromaDex undertakes no obligation to revise or
update this release to reflect events or circumstances after the
date hereof.
About ChromaDex:
ChromaDex Corp. (NASDAQ: CDXC) is the global authority on
nicotinamide adenine dinucleotide (NAD+), with a focus on the
science of healthy aging. The ChromaDex team, composed of
world-renowned scientists, works with independent investigators
from esteemed universities and research institutions around the
globe to uncover the full potential of NAD+. A vital coenzyme found
in every cell of the human body, NAD+ declines with age and
exposure to other everyday stressors. NAD+ depletion is a
contributor to age-related changes in health and vitality.
Setting the benchmark as the gold standard in scientific rigor,
safety, quality, and transparency, ChromaDex is the innovator
behind its clinically proven flagship ingredient, Niagen (patented
nicotinamide riboside, or NR), the most efficient and
superior-quality NAD+ booster available.
Niagen ® is the active ingredient in ChromaDex’s consumer
products, sold as the brand Tru Niagen ®, the number one
healthy-aging NAD+ supplement in the United States †. Clinically
proven to increase NAD+ levels, Tru Niagen is helping people around
the world transform the way they age (available at
www.truniagen.com ). ChromaDex supplies pharmaceutical-grade Niagen
® to U.S. FDA-registered 503B outsourcing facilities, which
compound and distribute intravenous and injectable Niagen ® for
clinics. These pharmaceutical-grade Niagen® products, known as
Niagen IV and Niagen injections, are available exclusively at
clinics with a prescription (www.niagenplus.com).
ChromaDex’s robust patent portfolio protects NR and other NAD+
precursors. ChromaDex maintains a website at www.chromadex.com,
where copies of press releases, news, and financial information are
regularly published.
† Based on the top-selling dietary supplement brands by revenue
per the largest U.S. e-commerce marketplace (as of
3/1/2023-2/29/2024).
About Restore Hyper Wellness:
Launched in Austin, Texas in 2015, Restore is expanding the
limits of personal health and performance, to help people do more
of what they love through personalized, science-backed therapies.
Restore delivers expert guidance and an extensive array of
cutting-edge wellness therapies integrated under one roof,
including Cryotherapy, Red Light Therapy, Infrared Sauna,
Compression, IV Drip Therapy, Intramuscular (IM) Shots, Mild
Hyperbaric Oxygen Therapy, Neveskin, Hydrafacial™, and more. With
225+ studios nationwide, Restore is the largest direct-to-consumer
proactive healthcare provider.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241107717521/en/
ChromaDex Media Contact: Kendall Knysch, Senior Director
of Media Relations & Partnerships 310-388-6706 ext. 689
kendall.knysch@chromadex.com
ChromaDex Investor Relations Contact: Ben Shamsian Lytham
Partners 646-829-9701 shamsian@lythampartners.com
ChromaDex (NASDAQ:CDXC)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
ChromaDex (NASDAQ:CDXC)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024
